Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Editorial] Discuss prostate cancer screening with your doctor

New draft recommendations released on April 11, this year, by the US Preventive Service Task Force (USPSTF) advise men aged 55–69 years to discuss prostate-specific antigen (PSA)-based screening for prostate cancer with their physicians. The change from previous recommendations, published in 2012, that counselled against PSA-based screening in all age groups is informed by two large randomised trials: one conducted in Europe and the other in the USA. The USPSTF concludes that while many men will experience potential harms of screening (false–positive results, overdiagnosis, and overtreatment), screening 1000 men can prevent one to two prostate cancer deaths and may prevent three men from developing metastatic prostate cancer.